Halozyme Therapeutics

Halozyme Therapeutics HALO Stock

$93.04   -2.881004%
Add to favorites
Market Cap
$10.61B
LOW - HIGH [24H]
$91.19 - $94.57
VOLUME [24H]
$3.91M
P/E Ratio
23.26
Earnings per share
$4.00
ISIN
US40637H1095
Price   Prediction

Halozyme Therapeutics Price Chart

Sorry, that's all we've gotfor now...

Halozyme Therapeutics (HALO) stock price today is 93.04 USD on Tech Market Large (-2.88% on the day). Updated .

Halozyme Therapeutics HALO Financial and Trading Overview

Halozyme Therapeutics stock price 93.04 USD
Previous Close 95.8 USD
Open 92.74 USD
Bid 88.1 USD x 100
Ask 97.58 USD x 100
Day's Range 91.19 - 94.57 USD
52 Week Range 61.23 - 134 USD
Volume 3.91M USD
Avg. Volume 2.23M USD
Market Cap 10.61B USD
Beta (5Y Monthly) 0.897
PE Ratio (TTM) 23.26
EPS (TTM) 4 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 119.89 USD

HALO Valuation Measures

Enterprise Value 13.13B USD
Trailing P/E 23.26
Forward P/E 8.784021
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 5.8850465
Price/Book (mrq) N/A
Enterprise Value/Revenue 7.283
Enterprise Value/EBITDA 11.511

Trading Information

Halozyme Therapeutics Stock Price History

Beta (5Y Monthly) 0.897
52-Week Change 38.90%
S&P500 52-Week Change 12.00%
52 Week High 134 USD
52 Week Low 61.23 USD
50-Day Moving Average 113.81 USD
200-Day Moving Average 85.75 USD

HALO Share Statistics

Avg. Volume (3 month) 2.23M USD
Avg. Daily Volume (10-Days) 2.62M USD
Shares Outstanding 114.01M
Float 112.71M
Short Ratio 6.19
% Held by Insiders 1.07%
% Held by Institutions 116.90%
Shares Short 13.65M
Short % of Float 15.68%
Short % of Shares Outstanding 11.97%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 26.93%
Operating Margin (ttm) 56.67%
Gross Margin 76.00%
EBITDA Margin 63.27%

Management Effectiveness

Return on Assets (ttm) 22.42%
Return on Equity (ttm) 216.37%

Income Statement

Revenue (ttm) 1.8B USD
Revenue Per Share (ttm) 15.45 USD
Quarterly Revenue Growth (yoy) 39.20%
Gross Profit (ttm) 1.37B USD
EBITDA 1.14B USD
Net Income Avi to Common (ttm) 485.42M USD
Diluted EPS (ttm) 4
Quarterly Earnings Growth (yoy) 41.00%

Balance Sheet

Total Cash (mrq) 1.07B USD
Total Cash Per Share (mrq) 9.42 USD
Total Debt (mrq) 3.28B USD
Total Debt/Equity (mrq) N/A
Current Ratio (mrq) 3.879
Book Value Per Share (mrq) -0.485

Cash Flow Statement

Operating Cash Flow (ttm) 898.27M USD
Levered Free Cash Flow (ttm) 427.85M USD

Profile of Halozyme Therapeutics

Country United States
State CA
City San Diego
Address 12390 El Camino Real
ZIP 92130
Phone 858 794 8889
Website https://halozyme.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 423

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Q&A For Halozyme Therapeutics Stock

What is a current HALO stock price?

Halozyme Therapeutics HALO stock price today per share is 93.04 USD.

How to purchase Halozyme Therapeutics stock?

You can buy HALO shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Halozyme Therapeutics?

The stock symbol or ticker of Halozyme Therapeutics is HALO.

Which industry does the Halozyme Therapeutics company belong to?

The Halozyme Therapeutics industry is Biotechnology.

How many shares does Halozyme Therapeutics have in circulation?

The max supply of Halozyme Therapeutics shares is 114.01M.

What is Halozyme Therapeutics Price to Earnings Ratio (PE Ratio)?

Halozyme Therapeutics PE Ratio is 23.26000000 now.

What was Halozyme Therapeutics earnings per share over the trailing 12 months (TTM)?

Halozyme Therapeutics EPS is 4 USD over the trailing 12 months.

Which sector does the Halozyme Therapeutics company belong to?

The Halozyme Therapeutics sector is Healthcare.

Halozyme Therapeutics HALO included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 23879.2 USD —
-2.25
8.33B USD — 23870.7 USD — 24939.62 USD — — 8.33B USD —
us Dow Jones U.S. Biotechnology In DJUSBT US 3862.13 USD —
-0.95
114.37M USD — 3854.21 USD — 3919.64 USD — — 114.37M USD —
us US Tech US Smart Pharmaceuticals NQSSPH US 2232.16 USD —
-2.21
— — 2228.96 USD — 2284.66 USD — — — —
us US Tech AlphaDEX Multi Cap Growt NQDXUSMLTCG US 3557.41 USD —
-2.29
— — 3555.54 USD — 3690.74 USD — — — —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
us US Tech Composite Total Return XCMP US 29515.56 USD —
-2.24
— — 29505.06 USD — 30826.03 USD — — — —
us US Tech Global Select Market Com NQGS US 11763.07 USD —
-2.26
— — 11758.76 USD — 12288.24 USD — — — —
us US Tech DM Ex Japan Large Mid Ca NQDMXJPLMAUD US 2100.38 AUD 1467.26 USD
<0.01
— — 2100.38 AUD 1467.26 USD 2100.38 AUD 1467.26 USD — — —
us US Tech Biotechnology NBI US 6901.37 USD —
-1.01
— — 6893.3 USD — 7033.67 USD — — — —
us US Tech Health Care IXHC US 1306.01 USD —
-1.39
— — 1303.72 USD — 1333.62 USD — — — —
us US Tech Biotechnology Total Retu XNBI US 7541.29 USD —
-1.01
— — 7532.47 USD — 7685.86 USD — — — —
$2.15T
Total marketcap
$75.62B
Total volume
BTC 57.95%   •   ETH 9.95%
Dominance
Select currency